Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1939 1
1945 1
1959 1
1961 2
1962 2
1964 3
1965 7
1966 14
1967 16
1968 13
1969 11
1970 9
1971 17
1972 30
1973 19
1974 29
1975 70
1976 94
1977 88
1978 83
1979 93
1980 106
1981 111
1982 118
1983 158
1984 186
1985 195
1986 217
1987 756
1988 1530
1989 1714
1990 1729
1991 1750
1992 1826
1993 1893
1994 1997
1995 1869
1996 2031
1997 2066
1998 2381
1999 2567
2000 2822
2001 3253
2002 2967
2003 3101
2004 3183
2005 3228
2006 3281
2007 3345
2008 3172
2009 3207
2010 3629
2011 3929
2012 4191
2013 3994
2014 4151
2015 4450
2016 4479
2017 4453
2018 4615
2019 4543
2020 4265
2021 3614
2022 2227
2023 1825
2024 988

Text availability

Article attribute

Article type

Publication date

Search Results

102,510 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y, Kuga H. Okamoto H, et al. Xenobiotica. 2020 Oct;50(10):1242-1250. doi: 10.1080/00498254.2020.1755909. Epub 2020 Apr 22. Xenobiotica. 2020. PMID: 32306807
Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7-8 with the topoisomerase I inhibitor DXd. In this study, we investigated the pharmacokinetics (PK), biodistribution, catabo …
Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of …
Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.
Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, Clarke RB, Howell SJ, Cappello AR, Martinez-Outschoorn UE, Peiris-Pagès M, Sotgia F, Lisanti MP. Lamb R, et al. Oncotarget. 2015 Jun 10;6(16):14005-25. doi: 10.18632/oncotarget.4159. Oncotarget. 2015. PMID: 26087309 Free PMC article.
DNA-PK is an enzyme that is required for proper DNA-repair and is thought to confer radio-resistance in cancer cells. ...Interestingly, genetic or pharmacological inhibition of DNA-PK in MCF7 cells is sufficient to functionally block mammosphere format …
DNA-PK is an enzyme that is required for proper DNA-repair and is thought to confer radio-resistance in cancer cells. ...Inter …
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.
Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, Chen X. Betts A, et al. AAPS J. 2019 May 22;21(4):66. doi: 10.1208/s12248-019-0332-z. AAPS J. 2019. PMID: 31119428 Free PMC article.
CD3 bispecific antibody constructs recruit cytolytic T cells to kill tumor cells, offering a potent approach to treat cancer. T cell activation is driven by the formation of a trimolecular complex (trimer) between drugs, T cells, and tumor cells, mimic …
CD3 bispecific antibody constructs recruit cytolytic T cells to kill tumor cells, offering a potent approach to treat cancer. …
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N. Furie R, et al. J Clin Invest. 2019 Mar 1;129(3):1359-1371. doi: 10.1172/JCI124466. Epub 2019 Feb 18. J Clin Invest. 2019. PMID: 30645203 Free PMC article. Clinical Trial.
RESULTS: Single doses of BIIB059 were associated with favorable safety and PK profiles. BIIB059 administration led to BDCA2 internalization on pDCs, which correlated with circulating BIIB059 levels. ...CONCLUSIONS: Single doses of BIIB059 were associated with favorable saf …
RESULTS: Single doses of BIIB059 were associated with favorable safety and PK profiles. BIIB059 administration led to BDCA2 internali …
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans.
Ayyar VS, Song D, Zheng S, Carpenter T, Heald DL. Ayyar VS, et al. J Pharmacol Exp Ther. 2021 Nov;379(2):134-146. doi: 10.1124/jpet.121.000805. Epub 2021 Aug 19. J Pharmacol Exp Ther. 2021. PMID: 34413198
The model bridged multiple PK-PD data sets in preclinical species (mice, rat, monkey) and successfully captured reported plasma pharmacokinetics and AT knockdown in a phase I ascending-dose study. ...The developed model successfully integrated and characterized rele …
The model bridged multiple PK-PD data sets in preclinical species (mice, rat, monkey) and successfully captured reported plasma ph …
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ. Munck JM, et al. Mol Cancer Ther. 2012 Aug;11(8):1789-98. doi: 10.1158/1535-7163.MCT-11-0535. Epub 2012 May 10. Mol Cancer Ther. 2012. PMID: 22576130 Free PMC article.
KU-0060648 is a dual inhibitor of DNA-PK and PI-3K in vitro. KU-0060648 was investigated in a panel of human breast and colon cancer cells. The compound inhibited cellular DNA-PK autophosphorylation with IC(50) values of 0.019 mumol/L (MCF7 cells) and …
KU-0060648 is a dual inhibitor of DNA-PK and PI-3K in vitro. KU-0060648 was investigated in a panel of human breast and colon cancer …
Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice.
Khot A, Matsueda S, Thomas VA, Koya RC, Shah DK. Khot A, et al. J Pharmacol Exp Ther. 2019 Mar;368(3):503-513. doi: 10.1124/jpet.118.252858. Epub 2019 Jan 8. J Pharmacol Exp Ther. 2019. PMID: 30622170 Free PMC article.
Here we have investigated whole-body pharmacokinetics (PK) of exogenously administered T cells in a mouse model of melanoma and have developed a physiologically based pharmacokinetic (PBPK) model to quantitatively characterize the data. ...Labeled T cells …
Here we have investigated whole-body pharmacokinetics (PK) of exogenously administered T cells in a mouse model of mela …
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L, Xue J, Zhang J, Li S, Liu D, Zhou T. Song L, et al. Eur J Pharm Sci. 2021 Mar 1;158:105584. doi: 10.1016/j.ejps.2020.105584. Epub 2020 Oct 9. Eur J Pharm Sci. 2021. PMID: 33039565 Review.
This study aimed to predict in vivo exposure-cytotoxicity relationship and human pharmacokinetics (PK) characteristics of M701, as well as to design optimal starting dose and effective dose for M701 first-in-human (FIH) study. ...Human PK model was integrated …
This study aimed to predict in vivo exposure-cytotoxicity relationship and human pharmacokinetics (PK) characteristics of M701 …
TSPO2 translocates 5-aminolevulinic acid into human erythroleukemia cells.
Manceau H, Lefevre SD, Mirmiran A, Hattab C, Sugier HR, Schmitt C, Peoc'h K, Puy H, Ostuni MA, Gouya L, Lacapere JJ. Manceau H, et al. Biol Cell. 2020 Apr;112(4):113-126. doi: 10.1111/boc.201900098. Epub 2020 Feb 5. Biol Cell. 2020. PMID: 31989647
RESULTS: ALA-induced PPIX accumulation in erythroleukemia cells (UT-7 and K562) was impaired by PK 11195, a competitive inhibitor of both transmembrane proteins TSPO (1 and 2). ...Overexpression of TSPO2 at the plasma membrane of erythroleukemia cells increas …
RESULTS: ALA-induced PPIX accumulation in erythroleukemia cells (UT-7 and K562) was impaired by PK 11195, a competitive inhibi …
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG, Rogliani P, Calzetta L, Cazzola M. Matera MG, et al. Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):239-245. doi: 10.1080/17425255.2018.1421170. Epub 2017 Dec 27. Expert Opin Drug Metab Toxicol. 2018. PMID: 29268638 Review.
Areas covered: The preclinical and clinical development of reslizumab, a humanized mAb against IL-5 that has been developed to block IL-5 bioactivity and reduce biologically available IL-5, are described with a particular focus on its pharmacodynamics (PK)/pharmacokinetic …
Areas covered: The preclinical and clinical development of reslizumab, a humanized mAb against IL-5 that has been developed to block IL-5 bi …
102,510 results
You have reached the last available page of results. Please see the User Guide for more information.